Session O: Oral Abstracts
Tracks
.
| Friday, September 8, 2017 |
| 1:00 PM - 2:00 PM |
| Manhattan Ballroom |
Speaker
Alison Marshall
Phd Student
The Kirby Institute
Restrictions for Reimbursement of Interferon-Free Direct Acting Antiviral Therapies for HCV Infection in Europe
1:00 PM - 1:15 PMBiography
Alison Marshall is an epidemiology PhD student in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Australia. Her research is primarily centered on the LiveRLife Study with specific attention to HCV and liver disease knowledge, liver disease assessment, and HCV treatment uptake.
Professor Jason Grebely
Professor
The Kirby Institute, UNSW
MD Brian Conway
Medical Director and President
Vancouver Infectious Diseases Centre
Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir + Ribavirin In People With HCV Genotype 1 And Recent Injecting Drug Use Or Receiving OST: D3FEAT Study
1:30 PM - 1:45 PMBiography
Dr. Brian Conway is the Director of the Vancouver Infectious Diseases Center in Vancouver, Canada.
Dr Shashi Kapadia
Instructor Of Medicine
Weill Cornell Medicine
Barriers to Hepatitis C Treatment Access Across the United States: Perspectives of Public Health Officials and Advocates
1:45 PM - 1:50 PMBiography
Dr. Kapadia is a fellow in Infectious Diseases at Weill Cornell Medicine and a resident in the Preventive Medicine Program. He is completing a Masters' of Science degree at the Weill Cornell Graduate School. His clinical and research interest is in hepatitis C treatment access disparities.
Håvard Midgard
MD
Oslo University Hospital
HCV Reinfection Following Successful Direct-Acting Antiviral Treatment among People who Inject Drugs: Preliminary Results from a Low-Threshold Treatment Setting
1:50 PM - 1:55 PMBiography
Håvard Midgard is a MD in gastroenterology and hepatology at Oslo University Hospital. He recently submitted his PhD thesis on management of HCV infection among people who inject drugs. His research has focused on treatment utake, reinfection and risk behaviours.
Professor Jason Grebely
Professor
The Kirby Institute, UNSW
HCV Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy: Co-Star Three-Year Follow-Up Study
1:55 PM - 2:00 PMBiography
Dr. Grebely is an Associate Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute of UNSW Sydney in Sydney, Australia.
